ONYX Pharmaceuticals 8-K Other Events

Exhibit 12.1

															Six Months
															Ended
	For the Year Ended December 31,														June 30,
	2004			2005			2006			2007			2008		2009
Income (loss) from continuing operations before income taxes	$	(46,756	)	$	(95,174	)	$	(92,681	)	$	(34,167	)	$	2,295	$	13,727
Fixed charges		271			285			296			569			409		244
Earnings as defined	$	(46,485	)	$	(94,889	)	$	(92,385	)	$	(33,598	)	$	2,704	$	13,971
Fixed charges:
Interest expense	$	149		$	68		$	—		$	—		$	—	$	—
Estimated interest component of rent expenses		122			217			296			569			409		244
Total fixed charges	$	271		$	285		$	296		$	569		$	409	$	244
Ratio of earnings to fixed charges	Note 1			Note 1			Note 1			Note 1				6.6		57.2

(1): For the fiscal years ended December 31, 2007, 2006, 2005 and 2004, our earnings were insufficient to cover fixed charges by $34.2 million, $92.7 million, $95.2 million and $46.8 million, respectively.